Skip to main content
. 2021 Apr 1;21:144. doi: 10.1186/s12876-021-01660-5

Table 4.

Effect of VSL#3® on fibrosis risk scores

Number of patients pre-VSL#3® Number of patients post-VSL#3® p valuea
F0–F2 Indeterminate F3–F4 F0–F1 Indeterminate F3–F4
NAFLD fibrosis risk score 1 11 7 3 9 7 0.16
FIB4 index 8 7 4 8 9 2 0.41

n = 19

F0–F2 = absence of significant fibrosis

F3–F4 = presence of significant fibrosis

aWilcoxon signed rank test